Pharmaceutical

China biotech RemeGen and its new U.S. partner Vor Bio are on a roll with their first-in-class autoimmune treatment telitacicept. Two weeks after reve...

The company's three-prong "Indivior Action Agenda" is all meant to boost U.S. growth of opioid use disorder treatment Sublocade.

A newly published report developed by a group of partners, including Sanofi, shines a light on the far-reaching impacts of well-funded community healt...

Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a reorganization that will see the...

Amid uncertainty over how the Trump administration would approach mRNA vaccines for the upcoming COVID-19 season, the FDA has approved updated shots f...

The St. Louis-based biotech hopes to submit an application for its leukemia and lymphoma therapy in 2027, if all goes well in an ongoing trial.

AMX0035 missed the goals of a study in progressive supranuclear palsy. Elsewhere, Novartis and BioArctic struck a deal, and Genentech started building...

Treatment with Verzenio helped people with a common type of early breast cancer liver longer than those given standard hormone therapy.

While the agency cleared vaccines from Pfizer, Moderna and Novavax broadly in older adults, it restricted eligibility in younger people to those with...

HUTCHMED has announced that Weiguo Su, CEO of the company, will take a leave of absence from his duties due to health reasons. As a result, the board...